Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA
Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). Patients & methods: Retrospective, observational study of IBM R MarketScan R...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2022-11-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: |
| _version_ | 1797785048596873216 |
|---|---|
| author | Lita Araujo Srikanth Kyatham Kristen G Bzdek Keiko Higuchi Nupur Greene |
| author_facet | Lita Araujo Srikanth Kyatham Kristen G Bzdek Keiko Higuchi Nupur Greene |
| author_sort | Lita Araujo |
| collection | DOAJ |
| description | Aim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in
people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies
(DMTs). Patients & methods: Retrospective, observational study of IBM R MarketScan R claims database.
PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December 2019)
were identified. “Index” was date of alemtuzumab initiation (prescription filled). Results: The study cohort
(n = 341) was primarily female (72%) with (mean ± standard deviation) age 45.1 ± 9.5 years. At index,
duration of MS was 5.3 ± 2.8 years. HCRU (inpatient/outpatient services), outpatient costs (including
MS-specific MRI and emergency room visits) and annualized relapse rate significantly reduced over the 2
years following initiation of alemtuzumab. DMT costs reduced over the same period. Conclusion: Health
economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for
treatment of MS, in this cohort from the USA. |
| first_indexed | 2024-03-13T00:48:38Z |
| format | Article |
| id | doaj.art-a9395ad0d04741748bedca1d6f06478a |
| institution | Directory Open Access Journal |
| issn | 2042-6313 |
| language | English |
| last_indexed | 2024-03-13T00:48:38Z |
| publishDate | 2022-11-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj.art-a9395ad0d04741748bedca1d6f06478a2023-07-08T11:53:32ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132022-11-0112110.2217/cer-2022-0127Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USALita Araujo0Srikanth Kyatham1Kristen G Bzdek2Keiko Higuchi3Nupur Greene4Sanofi, Cambridge, MA 02141, USAAxtria Inc., Berkeley Heights, NJ 07922, USASanofi, Cambridge, MA 02141, USASanofi, Cambridge, MA 02141, USASanofi, Cambridge, MA 02141, USAAim: Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs). Patients & methods: Retrospective, observational study of IBM R MarketScan R claims database. PwMS previously treated with DMTs and initiating alemtuzumab (1 January 2013 to 31 December 2019) were identified. “Index” was date of alemtuzumab initiation (prescription filled). Results: The study cohort (n = 341) was primarily female (72%) with (mean ± standard deviation) age 45.1 ± 9.5 years. At index, duration of MS was 5.3 ± 2.8 years. HCRU (inpatient/outpatient services), outpatient costs (including MS-specific MRI and emergency room visits) and annualized relapse rate significantly reduced over the 2 years following initiation of alemtuzumab. DMT costs reduced over the same period. Conclusion: Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the USA.alemtuzumabdisease-modifying therapies (dmts)healthcare costshealthcare resource utilization (hcru)inpatientoutpatientpeople with multiple sclerosis (pwms)relapsing-remitting multiple sclerosis (rrms)usa |
| spellingShingle | Lita Araujo Srikanth Kyatham Kristen G Bzdek Keiko Higuchi Nupur Greene Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA Journal of Comparative Effectiveness Research alemtuzumab disease-modifying therapies (dmts) healthcare costs healthcare resource utilization (hcru) inpatient outpatient people with multiple sclerosis (pwms) relapsing-remitting multiple sclerosis (rrms) usa |
| title | Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA |
| title_full | Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA |
| title_fullStr | Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA |
| title_full_unstemmed | Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA |
| title_short | Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA |
| title_sort | health economic outcomes of switching to alemtuzumab from other disease modifying therapies in people with multiple sclerosis in the usa |
| topic | alemtuzumab disease-modifying therapies (dmts) healthcare costs healthcare resource utilization (hcru) inpatient outpatient people with multiple sclerosis (pwms) relapsing-remitting multiple sclerosis (rrms) usa |
| work_keys_str_mv | AT litaaraujo healtheconomicoutcomesofswitchingtoalemtuzumabfromotherdiseasemodifyingtherapiesinpeoplewithmultiplesclerosisintheusa AT srikanthkyatham healtheconomicoutcomesofswitchingtoalemtuzumabfromotherdiseasemodifyingtherapiesinpeoplewithmultiplesclerosisintheusa AT kristengbzdek healtheconomicoutcomesofswitchingtoalemtuzumabfromotherdiseasemodifyingtherapiesinpeoplewithmultiplesclerosisintheusa AT keikohiguchi healtheconomicoutcomesofswitchingtoalemtuzumabfromotherdiseasemodifyingtherapiesinpeoplewithmultiplesclerosisintheusa AT nupurgreene healtheconomicoutcomesofswitchingtoalemtuzumabfromotherdiseasemodifyingtherapiesinpeoplewithmultiplesclerosisintheusa |